OnTracka

Chad Walkaden is the CEO and Founder of OnTracka, an Australian digital health company delivering compliant infrastructure for remote patient monitoring, real-world evidence generation, and hybrid clinical research across highly regulated therapeutic areas including oncology, obesity, endometriosis, and mental health.

Under his leadership, OnTracka has supported FDA-approved randomised clinical trials internationally, alongside TGA-aligned clinical research and real-world evidence programs in Australia. Across these programs, participant retention rates consistently exceeding 85 percent demonstrate the platform’s capacity to sustain engagement, preserve data integrity, and enable robust longitudinal evidence generation.

Chad also initiated the academic collaboration behind From Dose to Decision Making, supporting the development of practical frameworks for translating structured real-world data into regulatory-grade evidence. His work has enabled world-first longitudinal datasets in PTSD and psychedelic-assisted therapies, as well as the first structured dataset examining natural medicine use within Aboriginal and Torres Strait Islander communities. A Stage IV cancer survivor, Chad brings lived experience to building evidence-led digital health systems that clinicians, researchers, and regulators can trust.